The Association of Accessible Medicines (“AAM”) released a white paper on avoiding shortages and ensuring drug competition for patients in America. AAM is advocating for the uninterrupted availability of lower-cost generic and biosimilar medicines. In the paper, AAM asserts that by placing biosimilar medicines on a level competitive playing field with branded products – for example, by allowing biosimilar developers to rely on consistent reimbursement and formulary placement to justify significant development costs – policymakers can ensure availability of affordable medicines for patients.
